

**Summit Corporation plc**  
("Summit" or "the Company")

**NOTICE OF PRELIMINARY RESULTS**

**Oxford, UK, 4 May 2010**, Summit (AIM: SUMM), a UK drug discovery Company with partner funded programmes and an innovative Seglin<sup>TM</sup> (second generation iminosugar) technology platform for the discovery of new medicines, will be announcing its preliminary results for the year ended 31 January 2010 on Thursday, 6 May 2010.

- END -

**For more information, please contact:**

**Summit**

Steven Lee, PhD  
Richard Pye, PhD

Tel: +44 (0)1235 443939

**Singer Capital Markets (Nominated Adviser)**

Shaun Dobson / Claes Spång

Tel: +44 (0)20 3205 7500

**Peckwater PR**

Tarquin Edwards

Tel: +44 (0)7879 458 364

[tarquin.edwards@peckwaterpr.co.uk](mailto:tarquin.edwards@peckwaterpr.co.uk)

**About Summit**

Summit is an Oxford, UK based drug discovery company with a portfolio of partner funded drug programmes and an innovative technology platform called Seglins<sup>TM</sup> for the discovery of new medicines.

Summit's partnered drug programmes require no further investment from the Company but have contractual, success-based milestones potentially worth in excess of \$160 million and sales royalties rising to a low teen percentage. Partners include leading orphan drug specialist BioMarin Pharmaceuticals (Duchenne Muscular Dystrophy programme) and the Wellcome Trust (*C. difficile* programme).

**Seglin<sup>TM</sup> technology**

Seglin<sup>TM</sup> technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches. Summit's internal research is currently focussed in the high value therapy areas of type II diabetes and infectious diseases and the Company will further exploit the technology's wider potential through strategic alliances.

Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at [www.summitplc.com](http://www.summitplc.com).